@entity73333 and XXXX in the treatment of @entity2954 .

@entity1 @entity2954 @entity8657 @entity73333 @entity281 @entity1047
The antibacterial efficacy and tolerability of @entity73333 (EA) and @entity8657 (ES) were compared in 100 male @entity1 with @entity2954 ( @entity2954 ). The dosage of EA was 400 mg tid and that of ES 500 mg tid. Mean duration of treatment was ten days. When the final evaluation of the trial was made, the @entity1 material was divided into two groups. One group consisted of @entity1 with @entity1047 -positive culture before treatment, the other of @entity1047 -negative @entity1 with signs of @entity281 in the direct smear. There were 17 @entity1 with @entity281 in the EA-group, and the microbiological cure rate was 100%. In the ES-group there were 21 @entity1 with @entity281 and the microbiological cure rate was 95%. In the EA-group, the cure rate of @entity1047 -negative @entity2954 @entity1 was 78%, and the corresponding figure in the ES-group was 86%. There was no difference in the cure rates between the two groups on either drug. In the EA-group, 25 @entity1 (50%) reported side effects, in 22 these were gastrointestinal. In the ES-group, 26 @entity1 (52%) reported side effects; in 22 these were gastrointestinal. Two @entity1 in the EA-group discontinued the treatment because of gastrointestinal side effects. There were no differences between the groups in the frequency, severity and duration of side effects.
